📰 Quantitative Understanding News
Quantitative Understanding News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Quantitative Understanding. Real-time updates on events, politics, business and more.
June 12, 2024
1. In this randomized controlled trial, aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) compared with placebo. 2. The results for all 10 secondary endpoints were significantly improved with aficamten. Evidence Rating Level: 1 (Excellent) Study Rundown: HCM is one of the most common genetic heart diseases and is
May 22, 2024
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...
April 29, 2024
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European
April 5, 2024
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten
December 28, 2023
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
December 27, 2023
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant...
December 27, 2023
27.12.2023 - Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All ... Seite 1
December 26, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated CYTK today announced that members of its senior management will host…
December 26, 2023
SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM
December 14, 2023
/PRNewswire/ -- The "Hypertrophic Cardiomyopathy - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.coms offering. This report...